PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 100, Issue 6, Pages 713-729
Publisher
Wiley
Online
2016-09-19
DOI
10.1002/cpt.514
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
- (2016) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker
- (2016) RA Beckman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response
- (2016) Scott M Berry et al. Clinical Trials
- Efficiencies of platform clinical trials: A vision of the future
- (2016) Benjamin R Saville et al. Clinical Trials
- Innovation in the pharmaceutical industry: New estimates of R&D costs
- (2016) Joseph A. DiMasi et al. JOURNAL OF HEALTH ECONOMICS
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials
- (2016) James H. Suh et al. ONCOLOGIST
- The Impact of Adaptive Design on Portfolio Optimization
- (2016) Zoran Antonijevic Therapeutic Innovation & Regulatory Science
- Translating predictive biomarkers within oncology clinical development programs
- (2015) Robert A Beckman et al. Biomarkers in Medicine
- Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis
- (2015) Laurie J Legocki et al. BMC Medical Ethics
- Advancing Clinical Trials to Streamline Drug Development
- (2015) S. E. Bates et al. CLINICAL CANCER RESEARCH
- Lung Master Protocol (Lung-MAP)--A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
- (2015) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- The Signature Program: Bringing the Protocol to the Patient
- (2015) BP Kang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Emerging innovations in clinical trial design
- (2015) DA Berry CLINICAL PHARMACOLOGY & THERAPEUTICS
- From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients
- (2015) H-G Eichler et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics
- (2015) Mark R. Trusheim et al. DRUG DISCOVERY TODAY
- The Platform Trial
- (2015) Scott M. Berry et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:
- (2015) Caroline McNeil JNCI-Journal of the National Cancer Institute
- The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research
- (2015) Donald A. Berry Molecular Oncology
- All aboard: Will molecular tumor boards help cancer patients?
- (2015) Jeanne Erdmann NATURE MEDICINE
- Subclonal diversification of primary breast cancer revealed by multiregion sequencing
- (2015) Lucy R Yates et al. NATURE MEDICINE
- NCI-MATCH trial pushes cancer umbrella trial paradigm
- (2015) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- The Master Protocol Concept
- (2015) Mary W. Redman et al. SEMINARS IN ONCOLOGY
- NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:
- (2015) Caroline McNeil JNCI-Journal of the National Cancer Institute
- Real-Time Assessment of Wellness and Disease in Daily Life
- (2015) Dennis Ausiello et al. Big Data
- Adaptive designs for subpopulation analysis optimizing utility functions
- (2014) Alexandra C. Graf et al. BIOMETRICAL JOURNAL
- Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials
- (2014) C. Chen et al. CLINICAL CANCER RESEARCH
- An overview of FDA-approved new molecular entities: 1827–2013
- (2014) Michael S. Kinch et al. DRUG DISCOVERY TODAY
- Charting a path toward combination therapy for Alzheimer’s disease
- (2014) Diane Stephenson et al. Expert Review of Neurotherapeutics
- European perspective for effective cancer drug development
- (2014) Denis Lacombe et al. Nature Reviews Clinical Oncology
- Neratinib Graduates to I-SPY 3
- (2014) Cancer Discovery
- Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research
- (2014) Daniel Almirall et al. Translational Behavioral Medicine
- A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials
- (2013) H P Selker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials
- (2013) Scott M Berry et al. Clinical Trials
- ‘Master protocol’ aims to revamp cancer trials
- (2013) Heidi Ledford NATURE
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2
- (2013) B. M. Alexander et al. NEURO-ONCOLOGY
- Summary of the SRNT Treatment Network Webinar: Getting SMART About Developing Individualized Sequences of Health Interventions
- (2013) D. Almirall et al. NICOTINE & TOBACCO RESEARCH
- Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms
- (2013) Mark R Trusheim et al. PHARMACOGENOMICS
- Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug Development
- (2013) Lynn G. Baird et al. Therapeutic Innovation & Regulatory Science
- A "SMART" Design for Building Individualized Treatment Sequences
- (2012) H. Lei et al. Annual Review of Clinical Psychology
- White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens
- (2012) CLINICAL INFECTIOUS DISEASES
- Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
- (2012) H-G Eichler et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development
- (2012) Douglas Yee et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic challenges and possible policy actions to advance stratified medicine
- (2012) Mark R Trusheim et al. Personalized Medicine
- Design considerations, architecture, and use of the Mini-Sentinel distributed data system
- (2012) Lesley H. Curtis et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer
- (2012) R. A. Beckman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
- (2011) Laura J. Esserman et al. BREAST CANCER RESEARCH AND TREATMENT
- Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs
- (2011) Laura J. Esserman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study
- (2011) David J. Dabbs et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantifying factors for the success of stratified medicine
- (2011) Mark R. Trusheim et al. NATURE REVIEWS DRUG DISCOVERY
- Integrating predictive biomarkers and classifiers into oncology clinical development programmes
- (2011) Robert A. Beckman et al. NATURE REVIEWS DRUG DISCOVERY
- Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
- (2011) Hans-Georg Eichler et al. NATURE REVIEWS DRUG DISCOVERY
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Optimal Cost-Effective Designs of Phase II Proof of Concept Trials and Associated Go–No Go Decisions
- (2009) Cong Chen et al. Journal of Biopharmaceutical Statistics
- New medicines to improve control and contribute to the eradication of malaria
- (2009) Timothy N. C. Wells et al. NATURE REVIEWS DRUG DISCOVERY
- Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development
- (2009) Cong Chen et al. Statistics in Biopharmaceutical Research
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now